Karen M. Anderson Sells 30,526 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 30,526 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $19.03, for a total value of $580,909.78. Following the sale, the insider now owns 54,322 shares in the company, valued at approximately $1,033,747.66. This represents a 35.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Centessa Pharmaceuticals Trading Down 3.0 %

Shares of Centessa Pharmaceuticals stock opened at $17.26 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals plc has a 1 year low of $7.75 and a 1 year high of $19.09. The firm has a market cap of $2.28 billion, a PE ratio of -11.28 and a beta of 1.53. The company has a 50 day simple moving average of $16.78 and a two-hundred day simple moving average of $15.54.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CNTA has been the subject of several recent analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Buy” and an average target price of $25.83.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC lifted its position in Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after buying an additional 1,509 shares during the last quarter. Walleye Capital LLC purchased a new stake in Centessa Pharmaceuticals in the third quarter worth approximately $187,000. China Universal Asset Management Co. Ltd. grew its position in Centessa Pharmaceuticals by 99.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after acquiring an additional 6,785 shares during the last quarter. Finally, Harbour Capital Advisors LLC purchased a new position in shares of Centessa Pharmaceuticals during the third quarter worth approximately $259,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.